Integrated proteomic and metabolomic profiling of urine of renal anemia patients uncovers the molecular mechanisms of roxadustat
Molecular Omics · 20.03.2023 · 19 (6) · 473-483
DOI: 10.1039/d3mo00015j ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Omics, online erschienen am 20.03.2023. Verfasst von Xiaoe You und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen 518020, Guangdong, China. xin.zhou2@qq.com. Hauptthemen laut MEDLINE: Proteomics, Metabolomics, Renal Insufficiency, Chronic, Anemia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Roxadustat (FG-4592) is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) prescribed to patients with low hemoglobin associated with chronic kidney disease. Due to the various HIF-mediated adaptive responses, FG-4592 has attracted significant interest for therapeutic use against various diseases. However, the clinical application of Roxadustat remains limited due to a lack of understanding of its underlying mechanisms. Herein, we performed label-free quantitative liquid chromatography with tandem mass spectrometry (LC-MS–MS) proteomics and un-targeted metabolomics to study the protein and metabolite alterations in the urine of renal anemia patients before and after Roxadustat therapy. The results were validated by parallel reaction monitoring (PRM). A total of 46 proteins (including 15 upregulated and 31 downregulated proteins) and 207 metabolites were significantly altered after Roxadustat treatment in urine samples obtained from renal anemia patients. Then, the altered proteins were further validated by PRM. Finally, proteomics combined with metabolomics analysis revealed that the Ras signalling pathway, cysteine and methionine metabolism, arginine and proline metabolism, and cholesterol metabolism were the main pathways altered by Roxadustat treatment. The multi-omics analysis revealed that Roxadustat could alter the protein expression and reverse the potential metabolic changes to exert hypotensive, lipid metabolic regulation, and renoprotective effects in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen 518020, Guangdong, China. xin.zhou2@qq.com.
- Department of Nephrology, Shenzhen Peoples Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, Guangdong, Chin…
- Shenzhen Key Laboratory of Kidney Diseases, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 5180…
ORCID-Profile: Xiaoe You
Zitieren
APA
You, X., Guo, B., Wang, Z., Ma, H., Liu, L., Zhou, R., Zheng, Y., & Zhang, X. (2023). Integrated proteomic and metabolomic profiling of urine of renal anemia patients uncovers the molecular mechanisms of roxadustat. Molecular Omics, 19(6), 473-483. https://doi.org/10.1039/d3mo00015j
Vancouver
You X, Guo B, Wang Z, Ma H, Liu L, Zhou R, et al. Integrated proteomic and metabolomic profiling of urine of renal anemia patients uncovers the molecular mechanisms of roxadustat. Molecular Omics. 2023;19(6):473-483. doi:10.1039/d3mo00015j
BibTeX
@article{You2023,
author = {You, Xiaoe and Guo, Baochun and Wang, Zhen and Ma, Hualin and Liu, Lixia and Zhou, Ru and Zheng, Yaxuan and Zhang, Xinzhou},
title = {Integrated proteomic and metabolomic profiling of urine of renal anemia patients uncovers the molecular mechanisms of roxadustat},
journal = {Molecular Omics},
year = {2023},
volume = {19},
number = {6},
pages = {473--483},
doi = {10.1039/d3mo00015j}
}
EUVIMED